We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bluebird bio has teamed up with Gritstone Oncology to access another set of targets for its oncology cell therapies. The deal sees Bluebird pay $20 million upfront in return for 10 tumor-specific targets and T-cell receptors (TCRs).